Validating TDP1 as an Inhibition Target for the Development of Chemosensitizers for Camptothecin-Based Chemotherapy Drugs

Cancer chemotherapy sensitizers hold the key to maximizing the potential of standard anticancer treatments. We have a long-standing interest in developing and validating inhibitors of the DNA repair enzyme tyrosyl-DNA phosphodiesterase 1 (TDP1) as chemosensitizers for topoisomerase I poisons such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Euphemia, Patel, Jinal, Hollywood, Jennifer A., Zafar, Ayesha, Tomek, Petr, Barker, David, Pilkington, Lisa I., van Rensburg, Michelle, Langley, Ries J., Helsby, Nuala A., Squire, Christopher J., Baguley, Bruce C., Denny, William A., Reynisson, Jóhannes, Leung, Ivanhoe K. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593127/
https://www.ncbi.nlm.nih.gov/pubmed/34159519
http://dx.doi.org/10.1007/s40487-021-00158-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593127/
https://www.ncbi.nlm.nih.gov/pubmed/34159519
http://dx.doi.org/10.1007/s40487-021-00158-0

Ejemplares similares